← Back to Clinical Trials
Recruiting NCT02664831

NCT02664831 Immunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02664831
Status Recruiting
Phase
Sponsor MaineHealth
Condition Cardiac Arrest
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2016-01
Primary Completion 2027-01

Trial Parameters

Condition Cardiac Arrest
Sponsor MaineHealth
Study Type OBSERVATIONAL
Phase N/A
Enrollment 400
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2016-01
Completion 2027-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a prospective, observational study to investigate molecular mechanisms mediating the systemic inflammatory process, and changes to metabolism, and their impact on brain injury, survival, and functional outcomes after cardiac arrest. Investigators have shown that cardiac arrest induces changes in the numbers and properties of circulating immune cells, shifting the balance towards a pro-inflammatory phenotype and there is increased interest in the inflammatory pathways and the signaling mechanisms through which they are modulated. Participants will undergo blood sampling during 7 days following cardiac arrest, and analyses performed. Patient characteristics, clinical circumstances, and outcomes will be recorded and their associations with these inflammatory pathways characterized.

Eligibility Criteria

Inclusion Criteria: * Aged 18 years or older * Admitted to the intensive care unit after cardiac arrest episode * Unresponsive after resuscitation Exclusion Criteria: * Moribund / actively dying at the time of evaluation * Informed consent cannot be obtained within 24 hours of resuscitation * Hemoglobin less than 7.0 g/dL, active high-volume bleeding, or requiring a transfusion

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology